Render Target: STATIC
Render Timestamp: 2024-11-21T13:19:34.722Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:58:03.320
Product last modified at: 2024-10-16T22:45:13.372Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD33 (E6V7H) Rabbit mAb #60049

Filter:
  • IP
  • IF
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 70-80
    Source/Isotype Rabbit IgG
    Application Key:
    • IP-Immunoprecipitation 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunoprecipitation 1:100
    Immunofluorescence (Immunocytochemistry) 1:400 - 1:1600
    Flow Cytometry (Fixed/Permeabilized) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #53391.

    Protocol

    Specificity / Sensitivity

    CD33 (E6V7H) Rabbit mAb recognizes endogenous levels of total CD33 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human CD33 protein.

    Background

    CD33, a type I transmembrane protein, is a sialic acid-binding Ig-like lectin 3 (Siglec-3) of the Ig superfamily, and human CD33 binds preferentially to alpha-2, 6-linked sialic acid. Upon binding to its ligands, CD33 transduces inhibitory signaling through the immunoreceptor tyrosine-based inhibitory motif (ITIM) in its intracellular domain, inhibiting cellular functions such as phagocytosis. In addition, CD33 is also involved in other processes, such as adhesion (1-3). Due to its exclusive expression on hematopoietic cells, particularly the myeloid lineage and their progenitors, CD33 has been actively pursued as a therapeutic target against acute myeloid leukemia (AML) (4,5). CD33 may also be involved in Alzheimer’s Disease (AD) (6-8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.